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Reviewer #1 (Remarks to the Author): 
 
The authors of this manuscript, “Time-resolved in vivo ubiquitinome profiling by DIA-MS reveals 
Usp7 targets on a proteome-wide scale”, present a novel mass spectrometry-based approach for 
studying ubiquitinated proteins, and apply their approach to study the effects of several inhibitors of 
the deubiquitinase Usp7 on protein degradation. The authors sufficiently demonstrate the 
improvements made by their proposed ubiquitinome protocol, although unfortunately much of the 
novelty of using SDC and DIA has been recently “scooped” by the Hansen et al 2021 Nat Comms 
paper published in this journal. That said, there is quite a bit of informative, but downplayed, data 
on the implications of using DIA versus DDA that might be expanded to regain some novelty in that 
regard. Overall, the authors seem quite knowledgeable of the mass spectrometry-based 
ubiquitination field and have presented interesting datasets. I imagine the manuscript’s conclusions 
will be of interest to mass spectrometrists performing ubiquitin PTM work, and perhaps also assist 
drug discovery efforts geared towards degraders such as the ubiquitin-proteasome pathway. 
 
I recommend publication of the manuscript with the following major and minor revisions to support 




(1) Although the authors do mention the Hansen et al preprint in the Discussion, that work has now 
been published in this journal (Hansen et al 2021, Nat Comms). As the Hansen paper also used SDC 
and DIA for ubiquitination, the authors should adjust their language appropriately (e.g. use of 
“novel” is already a bit dated, as Hansen et al did it “first”). However, there is much room to 
compare/contrast the salient points of this work versus Hansen et al. As one example, Hansen et al 
relies on Spectronaut for DIA analysis, which is a closed-source and proprietary software, whereas 
the authors here are using a free and open-source software, DIA-NN. A few more detailed points 
below: 
 
(1a) Although the authors have done well to benchmark DIA-NN for ubiquitin modifications, there is 
no comparison of DIA-NN versus other software. I would like to see a comparison of DIA-NN versus 
Spectronaut (for the sake of comparing to Hansen et al) or, if a Spectronaut license is not possible, 
some other DIA software like IPF (Rosenberger et al 2017, Nat Biotech) or Thesaurus (Searle et al 
2019, Nat Methods). 
 
(1b) The authors claim novelty with a library-free DIA performing comparably to DIA analysis based 
on experimentally-generated spectral libraries, e.g. in the Methods, “Briefly, DIA-NN first generates a 
spectral library from DIA data using all identifications in specified raw files.” I would like a bit more 
elaboration on this point, ss to my knowledge none of the other predicted spectral library algorithms 
(MS2PIP, Prosit) can generate modified peptide spectra. Does DIA-NN work for other modifications 
as well? Does it predict retention times, like other predicted spectral library tools? What about 
multiply-modified peptides? 
 
(2) The authors use an unusual type of plot in Figures 4B and S3. These types of figures are usually 
shown as volcano plots, but here the author is using “standard error” instead of “p-value” on the 
vertical axis. I request the authors provide volcano plots for these figures, at least as supplemental 





- Pg 3 paragraph 2, “For example, while K11- and K48-linked chains can tag proteins for proteasomal 
degradation, ubiquitin conjugates on K63 tend to modulate protein-protein interactions”. It’s 
unclear if this refers to some specific protein with ubiquitinated K11, K48, and K63 residues, or if this 
means that the lysine can have 11-, 48-, or 63-ubiquitin moiety-long chains on a lysine. 
 
- Pg 3, paragraph 4, “By introducing an SDC-based lysis protocol [...]” the abbreviation “SDC” should 
be defined first before using the abbreviation. 
 
- Pg 3, paragraph 4, “[...] as well as significantly improve quantitative accuracy.” The authors show 
quantitative precision/reproducibility, but only show better accuracy in figure S7 which is actually a 
very interesting figure that isn’t mentioned at all in the text! Authors should use some text to 
describe that DIA improves quantitative accuracy per Fig S7. 
 
- Fig 1B - on average, how many lysine residues are ubiquitin-modified per protein? One 
ubiquitinated lysine per protein? Two? Six? 
 
- Pg 7, paragraph 2, “Although DIA-NN uses a rigorous approach to determine the false discovery 
rate (FDR) [...]” - including some plots of the target/decoy curves (e.g. such as those in Rosenberger 
et al 2017 Nat Methods) would also strengthen this argument that DIA-NN is properly controlling 
FDR. 
 




Reviewer #2 (Remarks to the Author): 
 
 
The manuscript from Steger et al. describes improvements to the methods used to characterize site 
specific protein ubiqutiination. Key advances in the paper include an optimized lysis protocol, a data 
independent analysis analytical method and a data processing approach. that takes advantage of 
neural networks. The authors employed their optimized DIA—MS method to characterize the 
ubiqutination events modulated by inhibitors of the deubiquitinase USP7. There, the authors 
compared DIA acquired DiGly data across four distinct small molecule inhibitors of USP7. Overall, 
many elements of this manuscript are convincing enough to say that the method works, and may 
even work very well. That said, there is one aspect of this protocol where there is the potential for a 
dramatic artifactual result, that if true, would profoundly alter conclusions about the comparative 
effectiveness of this method versus others. This is detailed below and will need to be addressed 
rigorously. On the USP7 substrate identification side, the results are overall interesting and 
impressive. The authors are commended for recognizing the valuable insights that come from being 
able to “accurately time ubiquitination and consequent changes in [protein] abundance. Acute 
treatments are key, and leveraging them herein brings rigor to the biology side of this story There 
also, an experiment that could be done which would markedly enhance the impact of the paper and 
that the authors are greatly encouraged to execute during revision. 
 
As noted, the biological experiments performed using proteasome and DUB inhibitors make it clear 
that the method described works to identify DiGly peptides. That said, a major premise of the paper 
is that the improved SDC based lysis protocol makes this method far superior to existing methods. 
That need not be the case for this paper to be acceptable for publication, but as written, it must be 
validated. In terms of validation, the authors have provided the perfunctory comparisons of 
numbers of identified peptides, %CV, etc. That said, all of these numbers could be dramatically 
affected by the possibility that the method is creating large numbers of artifactual peptides with 
isobaric 114.0429 Da mass additions that are nearly indistinguishable from DiGly modifications. 
Mann an colleagues previously reported this concern with regards to iodoacetamine (Nielsen et al. 
Nat Meth 2008), and in that paper proposed the use of chloroacetamide as was used here. In their 
paper, Mann and colleagues did note the potential for CAA (as used here) to generate the same 
artifactual DiGly-mimicking modifications if incubated at high temperature. That is precisely what 
was done here in the novel SDC lysis protocol, with 40 mM CAA incubation performed at 95C for 10 
min. To evaluate this, the authors should provide a systematic assessment of their SDC lysis protocol 
(+/- CAA treatment at 95C and lower temps), looking not in the DiGly enriched samples…but rather 
in the digested whole cell lysate. It remains possible that the profound increase in DiGly peptide 
sensitivity comes from the generation of a huge pool of artifactual features and the authors must 
show that this is not the case. 
 
As an aside, one way one can diagnose this will be to search unenriched digested lysates. If the DIA-
MS method is identifying any more than a handful of modified peptides (I.e. K48-Ub, K119-H2A), the 
artifact is a major issue. A confirmatory way to evaluate this is to look for peak doublets for features 
such as the K48 and K63 modified peptides from Ub in DiGly enriched samples. The bona fide and 
artifactual 114.0429 Da modified peptides nicely resolve on most every LC-MS setup. 
 
What happens to DiGly peptide number is CAA treatment is performed at lower temperatures? 
 
Authors should show some form of raw abundance data for the DiGly peptides of Ub and their 
abundances under MG132 and USP7-inhibitor treated conditions as a demonstration to the reader. 
A disconcerting thing about DIA data is the amount of processing that must be done blindly without 
the user having an opportunity to look in at the data. These sorts of demonstrations will help to 
provide confidence in the analytical assertions being made. 
 
In Suppl. Note 1, the authors describe an E.Coli mixing experiment. This would be an ideal case to 
test the CAA artifactual modification question since these bacterial to not express Ub. If DiGly 
peptides are identified in these samples prepared using the SDC lysis protocol, that would be clear 
evidence of the effect. 
 
Rather than showing peptide counts, can the authors provide data in the early figures to show the 
extent of increased abundances for individual DiGly peptides upon proteasome inhibition. Options 
would be histograms, bees warm dot plots, etc. A key question will be how many do not change, or 
go down…some certainly do as a result of Ub depletion and it would build confidence to see that 
those go down (e.g. K119-H2A). 
 
The other major point the authors should address relates to the specific versus off target effects of 
USP7 small molecule inhibitors. In the event that USP7 inhibitors are working through targets 
besides the DUB of interest, those would be effects that would be visible in USP7 KO or knockdown 
cells. IN other words, if the target is absent but the drug still has an acute effect, it makes clear that 
the compound is working through another enzyme. Moreover, the DUB KO or KD should also 
independently confirm many of the targets identified here, acknowledging that compensation will 
also complicate results of this experiment. Addition of a USP7 KO experiment would be a capstone 
piece of tdata for his paper. 
 
The term ‘ubiquitinomics’ feels awkward…is there any other term that can be used to describe this 
are of work. 
 
On p9, the text states that “due to cytotoxicity. Proteasome inhibitors cannot be utilized for studying 
protein ubiquitination in vivo”. This is untrue. Molecules such as bortezamib and carfilzomid are 
clinically approved molecules in spite of their toxicities, and indeed hit their targets in vivo. This 
statement should be revised to to ensure that it remains factually accurate, even while conveying 
the intended message. 
 
The very next sentence begins “We therefore tested…”. This is a logical disconnect and does not 
make sense relative to the text that comes before it. 
 
Overall, I did not find the figures overly informative due to the fact that the majority show high level 
overviews of the data, In addition to these, or in place of certain elements, it would be comforting to 
see more ‘raw’ data for key positive control features such as known USP7 substrates. 
Chromatographic traces convey how clean or noisy data are in a way that is often obscured when 
the data is aggregated as they are here and in other such papers. The authors have a chance to make 
a major impact, and this is a key piece that would help do so. It would be great to do so for some of 
the features so elegantly shown in Fig 4C 
 
Lastly, the one thing that seems missing from this paper is any text describing how the Neural 
Networks analysis method operates or how/why it is better. This was a major tenet of impact in the 
early text, but was not spoken about in any detail, nor were any demonstrative figures shown. 
 
Figure S7 has the y-axis value truncated in a way that obscures the true result. 
 
On p29, the methods describe two different STAGE tip protocols. When were each used? Are there 
any key performance differences between them that might affect data interpretation? 
 
 
Reviewer #3 (Remarks to the Author): 
 
The authors describe here a novel workflow for ubiquitomics, the analysis of ubiquitylated proteins 
in a biological sample. This workflow is based on a sample preparation protocol using an SDC 
(sodium deoxycholate)-based cell lysis, prior to the enrichment of the modification, followed by 
data-independent acquisition (DIA) coupled to a neural network-based data processing. 
This methodology increases significantly the sensitivity and the throughput of the current GlyGly 
peptidome analysis workflow. Finally, the authors applied this workflow to characterise four 




- The manuscript is well written and clearly presented. However, the use of the English language 
could be improved. 
- The experiments are well designed and the quality of the figures is good. 
- This study is of high interest to other researchers in the field. However, a very similar approach, 
SDC-based cell lysis followed by DIA analysis) has been published recently in this journal: Hansen, et 





- Lack of orthogonal validation of the described workflow using more basic biochemistry techniques 
to perform ubiquitylation assays. For example, doing GST-UBA pulldowns as in Hansen, et al., 2020 
(Fig S3) or performing Ubiquitin immunoprecipitations as in Akimov et al., 2018 
(https://doi.org/10.1038/s41594-018-0084-y; Figure 5). This would be particularly interesting for 
validating some of the USP7-dependent identified GG peptides. 
- The acquisition methods (LC-MS/MS measurements) are not comparable for DDA (more 
conservative) and DIA (more relaxed) and this could lead to different sensitivities. For instance, I 
consider the average of 4 data points low (8-10 data points would be my recommendation). Table S8 
describing the optimisation of the number of DIA segments is missing. 
- ~10% of the GG peptides identified by DDA do not overlap with the GG peptides identified by DIA. 




- The authors use Usp7 to refer to the human protein. The right nomenclature is USP7 and this 
should be amended. 
- The authors mention that simultaneously recording the dynamics of both proteome and 
ubiquitome is a strategy for capturing USP7 targets or substrates (i.e. in the abstract or on page 11). 
This is not correct since these techniques do not provide evidence for direct interaction and we 
cannot rule out that the observed effects might be a consequence of secondary ubiquitylation 
events. The should be more carefully reformulated across the manuscript. 
- deep neural network-based data processing is mentioned several times across the text. I brief 
description of such an approach would be useful for gaining access to a broader audience. 
Point-by-point response
Summary
We thank all Reviewers for their effort in reading our manuscript and for their thorough assessment of
our work, as well as for their insightful suggestions on how to improve it. We have now significantly
reworked the manuscript and have addressed all the concerns raised. The main changes of the paper
are as follows:
● We have included an experiment, showing that CAA treatment at high temperatures does not
cause di-carbamidomethylation of lysine residues (Supplementary Figure 1). We provide two
additional proofs in the underlying response, demonstrating that CAA does not induce
di-carbamidomethylation of lysines.
● We further optimised DIA-NN, substantially increasing the numbers of ubiquitinated peptides
identified and quantified. We reprocessed all data with this new software version and with
modified search parameters (maximum of 2 variable modifications/peptide instead of just one,
as used in the original manuscript). We chose these parameters to more closely reflect the
standard settings of MaxQuant and Spectronaut. To make our data better comparable to other
studies (such as the study by Hansen et al, see below), we also adjusted the counting of K-GG
peptides. In the original manuscript, we counted modified sequences (e.g.
XXM(Ox)XK(GG)X and XXMXK(GG)X would be counted twice, where X is any amino
acid), whereas in the revised manuscript, we count K-GG stripped sequences (the
abovementioned peptide would be counted just once).
● We also included several benchmark experiments (Figures 2, 3 and Supplementary Figure 8)
to demonstrate that DIA-NN significantly outperforms the alternative state-of-the art DIA data
processing software (Spectronaut) for analyzing ubiquitinomics raw data, at a comparably low
false discovery rate.
● We reworked the figures to make them more informative and revised the wording of the text.
We also performed several biological validation experiments. First, by reducing expression of
USP7 using siRNAs, we demonstrate that the observed USP7 inhibitor effects are on-target
(Figure 4 and Supplementary Figure 5). Second, we validate USP7 auto-regulation
biochemically using ubiquitin-binding domain pulldown and Western blotting as well as MS.
Finally, we likewise use ubiquitin-binding domain pulldown coupled to MS to validate the
ubiquitination (upon USP7 inhibition) of the identified USP7 targets (Supplementary Figure
6).
● To compare the different USP7 inhibitors in a more unbiased manner, we did not include any
fold-change cut-off in the revised manuscript (originally >2-fold) (see Figure 5 in both the
1
original and the revised manuscripts). As a result, the numbers of the correlation plot and the
Venn diagram changed slightly. However, the main conclusions are not affected in any way.
Reviewer #1 (Remarks to the Author):
The authors of this manuscript, “Time-resolved in vivo ubiquitinome profiling by DIA-MS reveals
USP7 targets on a proteome-wide scale”, present a novel mass spectrometry-based approach for
studying ubiquitinated proteins, and apply their approach to study the effects of several inhibitors of
the deubiquitinase USP7 on protein degradation. The authors sufficiently demonstrate the
improvements made by their proposed ubiquitinome protocol,
Thank you for your positive feedback!
although unfortunately much of the novelty of using SDC and DIA has been recently “scooped” by the
Hansen et al 2021 Nat Comms paper published in this journal.
We note that we posted a preprint of our work back-to-back with the study of Matthias Mann’s
laboratory on bioRxiv back in July 2020
(https://www.biorxiv.org/content/10.1101/2020.07.24.219055v1,
https://www.biorxiv.org/content/10.1101/2020.07.23.218651v1).
That said, there is quite a bit of informative, but downplayed, data on the implications of using DIA
versus DDA that might be expanded to regain some novelty in that regard.
We reworded the text to make it clearer that the potential of DIA over DDA is huge for ubiquitinomics
applications. In general, we significantly improved the manuscript to clearly show that our workflow
outperforms other already peer-reviewed methods.
Overall, the authors seem quite knowledgeable of the mass spectrometry-based ubiquitination field
and have presented interesting datasets. I imagine the manuscript’s conclusions will be of interest to
mass spectrometrists performing ubiquitin PTM work, and perhaps also assist drug discovery efforts
geared towards degraders such as the ubiquitin-proteasome pathway.
I recommend publication of the manuscript with the following major and minor revisions to support




(1) Although the authors do mention the Hansen et al preprint in the Discussion, that work has now
been published in this journal (Hansen et al 2021, Nat Comms). As the Hansen paper also used SDC
and DIA for ubiquitination, the authors should adjust their language appropriately (e.g. use of “novel”
is already a bit dated, as Hansen et al did it “first”).
Response 1: We acknowledge that the manuscript from Hansen et al got peer reviewed and published
much faster than ours and we now included the Nat Comms citation also in the introduction (present in
the discussion in the original version). Although we posted our work back-to-back on bioRxiv, as
stated above, we adjusted the language slightly (e.g. we omit statements like novel protocol). For
example, see abstract (Page 2, lines 4 and 5).
However, there is much room to compare/contrast the salient points of this work versus Hansen et al.
As one example, Hansen et al relies on Spectronaut for DIA analysis, which is a closed-source and
proprietary software, whereas the authors here are using a free and open-source software, DIA-NN. A
few more detailed points below:
(1a) Although the authors have done well to benchmark DIA-NN for ubiquitin modifications, there is
no comparison of DIA-NN versus other software. I would like to see a comparison of DIA-NN versus
Spectronaut (for the sake of comparing to Hansen et al) or, if a Spectronaut license is not possible,
some other DIA software like IPF (Rosenberger et al 2017, Nat Biotech) or Thesaurus (Searle et al
2019, Nat Methods).
Response 2: We agree that the quality of our paper will benefit from a side-by-side comparison of
DIA-NN with another frequently used software for DIA data analysis. To do so, we first processed 6
raw files from Hansen et al with the library-free setup in DIA-NN. Specifically, the samples were
derived from HEK293 cells treated with 10 µM MG-132 for 4 h and comprised three workflow
replicates (2 injection replicates for each of those, see Figure 1d, Hansen et al,
https://doi.org/10.1038/s41467-020-20509-1). This yielded an increase in K-GG remnant peptides of
more than 40% (Figure 2g of the revised manuscript).
We also used another set of raw files from Hansen et al (U2OS cells, DMSO-treated, Figure 3 of
Hansen et al) and processed them with the library-free search option in DIA-NN. Strikingly, in this
direct comparison, DIA-NN again quantified about 75% more K-GG peptides ( Figure 3e of the
revised manuscript).
Finally, we processed our E.coli/human K-GG data set with Spectronaut, showing that DIA-NN keeps
the false discovery rate low (comparable or better than MaxQuant and Spectronaut), while identifying
75% more human K-GG peptides than Spectronaut  and about four times more than MaxQuant
(Supplementary Figure 8 of the revised manuscript).
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(1b) The authors claim novelty with a library-free DIA performing comparably to DIA analysis based
on experimentally-generated spectral libraries, e.g. in the Methods, “Briefly, DIA-NN first generates a
spectral library from DIA data using all identifications in specified raw files.” I would like a bit more
elaboration on this point, as to my knowledge none of the other predicted spectral library algorithms
(MS2PIP, Prosit) can generate modified peptide spectra. Does DIA-NN work for other modifications
as well? Does it predict retention times, like other predicted spectral library tools? What about
multiply-modified peptides?
Response 3: Indeed, prediction of modified peptide spectra has been lagging behind. Only recently it
was successfully applied using a number of different algorithms. The most general way to implement
this is to consider modified amino acids (e.g. K-GG or phospho-Ser) as 21st, 22nd, … types of amino
acids. K-GG would therefore be simply treated as unmodified amino acids, and the deep learning
algorithm would be oblivious to its relation to a lysine. This idea is discussed, for example, in a
recently published paper by the Cox group (DeepMass:Prism,
https://www.nature.com/articles/s41592-019-0427-6). Another way is to encode each residue in the
peptide as a pair of numbers - one for the amino acid, and another one for the modification (zero if no
modification is present). This approach is used in pDeep2 and pDeep3, which are publicly available
tools for modified peptide spectra prediction
(https://pubs.acs.org/doi/abs/10.1021/acs.analchem.9b01262,
https://www.biorxiv.org/content/10.1101/2020.09.13.295105v1). In both cases, an arbitrary number of
modified residues is theoretically supported, although the prediction performance might vary. It
appears that Spectronaut (starting from version 14) likewise uses deep learning for spectra prediction,
although its method is undisclosed and unpublished.
The module that is currently used for modified peptide prediction (spectra, retention times and ion
mobilities) in DIA-NN (since Jan 2020) is not novel idea-wise, therefore we haven’t published it.
However, there are a number of technical optimisations in it, which we intend to publish in the future
as part of a larger project. It aims at enabling high quality prediction of spectra, RTs and ion mobilities
for peptides with arbitrary modifications.
That said, we plan the next major release of DIA-NN for July (that is, before the present paper will be
published), and it will come with extensive documentation describing all its features, including
prediction of modified peptide spectra by deep learning. Apart from K-GG, variable modifications
supported by DIA-NN’s deep learning predictor are M(ox), N-term acetylation, phospho (STY) and
deamidation (NQ), and DIA-NN supports any number of modified residues per peptide. We consider
these modifications beyond the scope of this work, but do plan to benchmark them in future works.
Of note, DIA-NN also features a more simplistic predictor (introduced previously
https://www.nature.com/articles/s41592-019-0638-x) based on MS Simulator, which can be trained by
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the user to predict y-series fragmentation and retention times for peptides bearing arbitrary
modifications. This functionality is not used in the present work but all relevant documentation can be
found in the manual of DIA-NN.
In summary, we believe that with respect to data processing, the novelty and the strength presented in
here, are the combination of previously described features of  DIA-NN (primarily the excellent
performance of the neural network classifier, especially in library-free mode
https://www.nature.com/articles/s41592-019-0638-x, Supp. Fig. SN8.2)  and a new PTM-scoring
module (described in Methods of the current work). We demonstrate that this combination clearly
outperforms the existing state-of-the-art software (Spectronaut) for ubiquitinome analyses. Once
online, we will suggest the present paper as reference for DIA-NN users who are interested in PTM
data processing.
(2) The authors use an unusual type of plot in Figures 4B and S3. These types of figures are usually
shown as volcano plots, but here the author is using “standard error” instead of “p-value” on the
vertical axis. I request the authors provide volcano plots for these figures, at least as supplemental
figures, because these plots are so unusual for proteomics data.
Response 4: We agree that the scientific community is used to seeing volcano plots with p-values
instead of standard errors on the y-axis. We changed the plots in Figure 4b and Supplementary Figures
3 and 7 accordingly. Thank you for this suggestion!
Minor points:
- Pg 3 paragraph 2, “For example, while K11- and K48-linked chains can tag proteins for proteasomal
degradation, ubiquitin conjugates on K63 tend to modulate protein-protein interactions”. It’s unclear if
this refers to some specific protein with ubiquitinated K11, K48, and K63 residues, or if this means
that the lysine can have 11-, 48-, or 63-ubiquitin moiety-long chains on a lysine.
Response 5: We changed this statement to make it clear that proteins modified with K63-linked
ubiquitin chains modulate protein-protein interactions (Page 3, line numbers 18-19). (…For example,
while K11- and K48-linked chains can tag proteins for proteasomal degradation, attachment of
K63-linked ubiquitin conjugates to target proteins tends to modulate protein-protein interactions.)
- Pg 3, paragraph 4, “By introducing an SDC-based lysis protocol [...]” the abbreviation “SDC” should
be defined first before using the abbreviation.
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Response 6: Thanks for spotting this inconsistency! We have changed it to: ...a sodium deoxycholate
(SDC)-based…(Page 3, line number 26).
- Pg 3, paragraph 4, “[...] as well as significantly improve quantitative accuracy.” The authors show
quantitative precision/reproducibility, but only show better accuracy in Supplementary Figure 7 which
is actually a very interesting figure that isn’t mentioned at all in the text! Authors should use some text
to describe that DIA improves quantitative accuracy per Fig S7.
Response 7: We fully agree that this is a very important finding and this should be better highlighted.
On page 7, line numbers 11-12, we mention that DIA-NN provides excellent quantitative accuracy and
we refer to supplementary note 2. We now additionally refer to Supplementary Figure 9 (which was
Figure S7 in the originally submitted manuscript) to make it easier for the reader to locate the data.
- Fig 1B - on average, how many lysine residues are ubiquitin-modified per protein? One ubiquitinated
lysine per protein? Two? Six?
Response 8: There are 6 modified lysine residues per protein on average and we have included this in
the main text of the revised manuscript (Page 4, line numbers 22-23), In total, we identified 41,094
K-GG remnant peptides and on average found 6 –GG modified lysine residues per protein.)
- Pg 7, paragraph 2, “Although DIA-NN uses a rigorous approach to determine the false discovery rate
(FDR) [...]” - including some plots of the target/decoy curves (e.g. such as those in Rosenberger et al
2017 Nat Methods) would also strengthen this argument that DIA-NN is properly controlling FDR.
Response 9: We routinely include FDR-validating plots in our works, and DIA-NN’s performance with
regards to identification confidence has been validated already multiple times and on different types of
data, clearly demonstrating its reported FDR estimates are actually very conservative
(https://www.nature.com/articles/s41592-019-0638-x,
https://www.nature.com/articles/s41587-021-00860-4,
https://www.biorxiv.org/content/10.1101/2021.03.08.434385v1). To our knowledge, no other DIA
software has been validated that strictly. For example, Spectronaut has not been validated for false
discovery rate of modified peptide detection. Rather, the work by Bekker-Jensen et al. has established
that the false localisation rate of phosphosites is controlled at about 3%, on a selected set of spike-in
peptides (https://doi.org/10.1038/s41467-020-14609-1). Similarly, Thesaurus (part of EncyclopeDIA)
has also been shown to control false localisation rate at 7%
(https://doi.org/10.1038/s41592-019-0498-4).
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In the present work, however, we refrain from claiming that the FDR estimates for modified peptides
are exact, but rather demonstrate that the FDR is low and well-controlled (at about ~1%, when filtered
at 1% q-value).
The primary reason for this is that in a ‘real’ experiment featuring a K-GG-enriched human sample,
the effective FDR is likely to be significantly lower than what we have estimated for our
K-GG-enriched human + non-enriched E.coli benchmark experiment (see Supplementary Figure 8).
That is, the human-E.coli benchmark is conservative and provides an upper FDR estimate.
Indeed, if we exaggerate and assume that every single lysine in the sample bears a -GG adduct, then
there would not be any need for an extra PTM-specific scoring module. The problem arises when
unmodified peptides are present in the sample, which is the case for ubiquitinomics. These can be
mistaken as modified peptides and need to be spotted by the PTM-scoring module. In DIA-NN, this is
implemented in such a way as to provide conservative estimates regardless of whether unmodified
peptides are present, by relying, to a significant extent, on direct MS2-level evidence for fragment ions
containing the modified residue(s). That’s why it performs very well even in the very strict
human-E.coli benchmark experiment. We suspect that the implementation in Spectronaut is similar (as
it also controls the FDR well in our E.coli/human benchmark experiment).
- Fig 4D profiles of log2 fold changes would benefit from error bars.
Response 10: Makes total sense, we included those in the revised manuscript (Figure 4d). Thank you
for the suggestion!
Reviewer #2 (Remarks to the Author):
The manuscript from Steger et al. describes improvements to the methods used to characterize site
specific protein ubiqutiination. Key advances in the paper include an optimized lysis protocol, a data
independent analysis analytical method and a data processing approach. that takes advantage of neural
networks. The authors employed their optimized DIA—MS method to characterize the ubiqutination
events modulated by inhibitors of the deubiquitinase USP7. There, the authors compared DIA acquired
DiGly data across four distinct small molecule inhibitors of USP7. Overall, many elements of this
manuscript are convincing enough to say that the method works, and may even work very well.
Thank you very much for your positive feedback!
That said, there is one aspect of this protocol where there is the potential for a dramatic artifactual
result, that if true, would profoundly alter conclusions about the comparative effectiveness of this
method versus others. This is detailed below and will need to be addressed rigorously.
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This is a very valid concern and we addressed this with three experiments. We suggest including only
one of those experiments in the manuscript (see details below).
On the USP7 substrate identification side, the results are overall interesting and impressive.
Thank you!
The authors are commended for recognizing the valuable insights that come from being able to
“accurately time ubiquitination and consequent changes in [protein] abundance. Acute treatments are
key, and leveraging them herein brings rigor to the biology side of this story There also, an experiment
that could be done which would markedly enhance the impact of the paper and that the authors are
greatly encouraged to execute during revision.
We provide one validation experiment using siRNA-mediated knock-down of USP7 (see details
below).
As noted, the biological experiments performed using proteasome and DUB inhibitors make it clear
that the method described works to identify DiGly peptides. That said, a major premise of the paper is
that the improved SDC based lysis protocol makes this method far superior to existing methods. That
need not be the case for this paper to be acceptable for publication, but as written, it must be validated.
We now provide the requested validation experiments, please see below.
In terms of validation, the authors have provided the perfunctory comparisons of numbers of identified
peptides, %CV, etc. That said, all of these numbers could be dramatically affected by the possibility
that the method is creating large numbers of artifactual peptides with isobaric 114.0429 Da mass
additions that are nearly indistinguishable from DiGly modifications. Mann an colleagues previously
reported this concern with regards to iodoacetamine (Nielsen et al. Nat Meth 2008), and in that paper
proposed the use of chloroacetamide as was used here. In their paper, Mann and
colleagues did note the potential for CAA (as used here) to generate the same artifactual
DiGly-mimicking modifications if incubated at high temperature. That is precisely what was done here
in the novel SDC lysis protocol, with 40 mM CAA incubation performed at 95C for 10 min.
Response 11: Matthias Mann and colleagues indeed reported that IAA can induce
di-carbamidomethylation of lysine residues, resulting in the addition of a 114.0429 Da mass tag that is
indistinguishable from a K-GG adduct in terms of added mass to the peptide. Mann and colleagues
however failed to detect di-carbamidomethylation of lysines when treating peptides with CAA at room
temperature. Nevertheless, one can speculate that CAA treatment, along with incubation at high
temperatures, could induce di-carbamidomethylation of lysines. However, the chemical structures of
di-glycine lysine  and  di-carbamidomethylated lysine largely differ from each other (Figure 1 of this
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response). Thus, it is very unlikely that the monoclonal K-GG antibodies used for enrichment of
ubiquitin remnant peptides would recognize a di-carbamidomethylated lysine residue. Nonetheless, it
is possible that a small fraction of peptides with di-carbamidomethylated lysines would be
non-specifically bound to the sepharose matrix used for immunoprecipitation of K-GG peptides. We
therefore performed three experiments to exclude that CAA treatment at high temperatures causes an
increase of MS-detectable peptides containing K residues with a mass shift of 114.0249 Da (see
below).
Response Figure 1: Chemical structures of a (a) di-carbamidomethylated and (b) -GG-modified
lysine residue
To evaluate this, the authors should provide a systematic assessment of their SDC lysis protocol (+/-
CAA treatment at 95C and lower temps), looking not in the DiGly enriched samples…but rather in the
digested whole cell lysate. It remains possible that the profound increase in DiGly peptide sensitivity
comes from the generation of a huge pool of artifactual features and the authors must show that this is
not the case.
Response 12: Thank you for actively proposing an experiment for addressing this potential issue. As
suggested, to verify this, we lysed HCT116 cells in SDC buffer without CAA, followed by heating to
95°C. After cooling to room temperature, we added 40 mM CAA to all samples and then incubated
them at 35/50/65/80/95°C for 10 min. We then processed the samples for whole proteome MS analysis
and  acquired the data in DDA, followed by searching the resulting raw files with MaxQuant (standard
settings, inclusion of K-GG as variable modification, match-between-runs disabled). This revealed that
only a handful of K-GG peptides were identified in all conditions (well within the expected false
discovery rate of the processing software) and that there was no temperature effect.
We present this data in Supplementary Figure 1A of the revised manuscript. We revised the
corresponding section in the main text accordingly (Page 4, starting from line number 13).
As an aside, one way one can diagnose this will be to search unenriched digested lysates. If the
DIA-MS method is identifying any more than a handful of modified peptides (I.e. K48-Ub,
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K119-H2A), the artifact is a major issue. A confirmatory way to evaluate this is to look for peak
doublets for features such as the K48 and K63 modified peptides from Ub in DiGly enriched samples.
The bona fide and artifactual 114.0429 Da modified peptides nicely resolve on most every LC-MS
setup.
Response 13: Thank you for proposing another experiment. We searched a non-enriched proteome raw
file (proteome samples shown in Figure 4, i.e. USP7i time course) with K-GG as variable modification
(library-free mode in DIA-NN). These samples were lysed with SDC buffer (including 40 mM CAA,
heated to 95°C for 10 min) as described in the methods section. As rightly pointed out by the referee,
there should be little, if any at all, K-GG peptides detectable in such an analysis; hence, some of the
identified K-GG peptide most likely represent either a false positive identification or an artificially
introduced di-carbamidomethylation (114.0249 Da) on a lysine residue. This revealed only 275 K-GG
peptide precursors, in contrast to the 144,200 precursors quantified in total (Figure 2 of this response).
Besides validating that the false discovery rate for K-GG peptides is well below 1% (since 275 /
144,200 = 0.002), we conclude that despite the high concentration of CAA in the lysis buffer and the
heating step at 95°C, there is no significant artificial di-carbamidomethylation (114.0249 Da) of lysine
residues detectable.
Response Figure 2: K-GG peptide precursors identified in a whole proteome tryptic digest from
HCT116 cells lysed with SDC buffer
HCT116 cells were lysed with SDC buffer (1% SDC, 10 mM TCEP, 40 mM CAA, 75 mM Tris-HCl)
and heated at 95°C for 10 min. The proteins were digested using trypsin and the resulting peptides
desalted. 800 ng of the digest were injected into the mass spectrometer and the data acquired in DIA
mode using a 125 min LC gradient. The data was processed with DIA-NN, employing a library-free
search strategy with deep learning for prediction of retention times and peptide spectra. K-GG was
10
included as variable modification. This revealed 275 peptide precursors harboring a K-GG
modification, in contrast to the 143,925 unmodified peptides detected (that is only 0.2% of all peptides
reported were K-GG).
What happens to DiGly peptide number is CAA treatment is performed at lower temperatures?
Response 14: Thank you for the suggestion. However, we think that the results obtained with such a
setup would be inconclusive. For cell lysis in SDC buffer, cells must be heated to high temperatures
and if we did not add CAA to the buffer, DUBs would be inhibited less efficiently. Consequently, SDC
buffer containing CAA would possibly identify more K-GG peptides, but this would not necessarily be
an artifact but rather the inhibitory effect of CAA towards DUBs. We therefore did not perform this
experiment, but hope that the two experiments described earlier in this response, as well as an
additional experiment described below (Response Figure 3), provide convincing evidence that CAA
treatment at high temperatures does not introduce artificial di-carbamidomethyl-lysine modifications.
Authors should show some form of raw abundance data for the DiGly peptides of Ub and their
abundances under MG132 and USP7-inhibitor treated conditions as a demonstration to the reader. A
disconcerting thing about DIA data is the amount of processing that must be done blindly without the
user having an opportunity to look in at the data. These sorts of demonstrations will help to provide
confidence in the analytical assertions being made.
Response 15: K-GG peptides derived from Ubiquitin are highly abundant and are among the most
strongly enriched peptides by the K-GG-specific antibodies. Upon MG-132 treatment, their signal is
saturated in the MS measurements. To quantify K-GG peptides derived from Ubiquitin, one would
need to perform either a  SILAC experiment (similar to Akimov et al, doi:
10.1038/s41594-018-0084-y) or use isotopically labeled standards (see Xu et al, doi:
10.1016/j.cell.2009.01.041). In both of these publications, it was demonstrated that MG-132 treatment
leads to an increase of all Ubiquitin chain types. We therefore consider this experiment outside the
scope of this study.
However, we included raw data for several experiments in the revised manuscript. For example, the
bee swarm dot plot in Figure 3B shows Log2 fold changes of MG-132 vs DMSO treated cells. It
demonstrates that most detected K-GG peptides are upregulated upon MG-132. However, some
peptide quantities are downregulated upon MG-132 treatment, including H2A-K119. This site along
with other control sites are highlighted in the plot.
Additionally, we show protein abundances for targets identified in the ubiquitin domain pulldown
experiment, which is presented in Supplementary Figure 6 of the revised manuscript. We included a
set of supplementary tables (see Supplementary Data 1-11 for the different experiment), in which we
comprehensively included most raw data acquired for this study.
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In Suppl. Note 1, the authors describe an E.Coli mixing experiment. This would be an ideal case to test
the CAA artifactual modification question since these bacterial to not express Ub. If DiGly peptides
are identified in these samples prepared using the SDC lysis protocol, that would be clear evidence of
the effect.
Response 15: We performed the following experiment: using commercially available tryptic digest
from E.coli, we either resuspended the peptides in 0.1% formic acid or in SDC buffer. We then heated
the SDC-solubilized peptides to 95°C for 10 minutes. Following desalting, resuspension in 0.1%
formic acid and concentration estimation, we injected 800 ng of SDC- and formic acid-solubilized
peptides into the mass spectrometer (4 injection replicates each), acquiring the data in DDA mode.
MaxQuant quantified about 9,000 E.coli peptides in each sample and found 11 and 10 K-GG peptides
on average, for SDC-lysed and formic acid-solubilized peptides, respectively. Stringent filtering of the
data (posterior error probability (PEP)<0.001) drastically reduced the K-GG IDs (Figure 3 of this
response). Also in this case, we conclude that CAA treatment at 95°C does not introduce artificial
K-GG mimicking peptides.
Response Figure 3: K-GG peptides identified in a tryptic digest of E. coli
10 µg of a tryptic digest from E. coli (Waters (186003196)) were resuspended in either 0.1% formic
acid or SDC buffer (including 40 mM CAA). The SDC lysate was further processed by heating it to
95°C for 10 minutes. Subsequently, peptides in the SDC buffer were desalted. Both peptide pools
were then injected into the MS and the data acquired in DDA mode. The database search was done
using MaxQuant (standard settings, no match between runs, K-GG as variable modification). K-GG
and total peptides were counted using the ‘modification specific peptide’ output from MaxQuant. The
left bar plot shows all quantified E.coli peptides, whereas the plot on the right shows K-GG peptides
with posterior error probability (PEP)< 0.001. SDC= sodium deoxycholate, FA= formic acid.
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Rather than showing peptide counts, can the authors provide data in the early figures to show the
extent of increased abundances for individual DiGly peptides upon proteasome inhibition. Options
would be histograms, bees warm dot plots, etc. A key question will be how many do not change, or go
down…some certainly do as a result of Ub depletion and it would build confidence to see that those go
down (e.g. K119-H2A).
Response 16: Thank you for the suggestion. We show a bee swarm dot plot of individual log2 fold
changes (MG132 vs DMSO) of K-GG peptides. This revealed that the majority of peptide intensities
increase upon MG-132 treatment. However, there are peptides that decrease, and those include
K119-H2A. We present this data in Figure 3B of the revised manuscript and modified the main text
accordingly (see Page 9, starting from line number 34).
The other major point the authors should address relates to the specific versus off target effects of
USP7 small molecule inhibitors. In the event that USP7 inhibitors are working through targets besides
the DUB of interest, those would be effects that would be visible in USP7 KO or knockdown cells. IN
other words, if the target is absent but the drug still has an acute effect, it makes clear that the
compound is working through another enzyme. Moreover, the DUB KO or KD should also
independently confirm many of the targets identified here, acknowledging that compensation will also
complicate results of this experiment. Addition of a USP7 KO experiment would be a capstone piece
of tdata for his paper.
Response 17: Although we have shown that four structurally distinct inhibitors targeting USP7 have
similar effects (Figure 5 of the submitted manuscript), we now included an additional validation
experiment showing that FT671 is a selective USP7 inhibitor. We down-regulated USP7 with 2
different pools of siRNAs. After 48 h of knock-down, we achieved an approximately 4-fold
downregulation of the protein with both siRNAs (Supplementary Figure 5 of the revised manuscript).
We quantified both the proteome and the ubiquitinome after DMSO or FT671 treatment (5 minutes),
for siCTRL and siUSP7 samples, to a depth of 10,000 proteins and 40,000 K-GG peptides in each
measurement. Analysis of the proteome revealed drastic changes in global protein expression upon
USP7 knockdown, including a significant stabilization of p53 with both siRNAs, as expected (see
Supplementary Figure 5 and Supplementary Data 9 of the manuscript).
In the ubiquitinome, we found an overall strongly decreased degree of regulation after compound
treatment when USP7 expression was reduced using siRNAs. In fact, compared to cells transfected
with a control siRNA,  in siUSP7-treated cells, ubiquitination sites of virtually all putative USP7
substrates pinpointed in this study were induced less strongly upon compound treatment. We included
this data in Figure 4 of the revised manuscript and modified the text (Page 13, starting from line 25).
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The term ‘ubiquitinomics’ feels awkward…is there any other term that can be used to describe this are
of work.
Response 18: We are not aware of any alternative term for ubiquitinomics. We tried to change the
language slightly and to replace ubiquitinomics with MS-based ubiquitin profiling, whenever
appropriate.
On p9, the text states that “due to cytotoxicity. Proteasome inhibitors cannot be utilized for studying
protein ubiquitination in vivo”. This is untrue. Molecules such as bortezamib and carfilzomid are
clinically approved molecules in spite of their toxicities, and indeed hit their targets in vivo. This
statement should be revised to to ensure that it remains factually accurate, even while conveying the
intended message.
Response 19: It is true that proteasome inhibitors are used for cancer therapy and to avoid confusion,
we removed the sentence from the text (Page 9, line number 25).
The very next sentence begins “We therefore tested…”. This is a logical disconnect and does not make
sense relative to the text that comes before it.
Response 20: Thank you for the careful assessment. We have changed the sentence to as follows (Page
9, line 25):
To determine whether our DIA-MS method was suited for high coverage ubiquitinomics in the
physiological context and in case of low protein input, we quantified K-GG peptides derived from
different protein input amounts of either MG-132- or DMSO-treated cells.
Overall, I did not find the figures overly informative due to the fact that the majority show high level
overviews of the data, In addition to these, or in place of certain elements, it would be comforting to
see more ‘raw’ data for key positive control features such as known USP7 substrates.
Chromatographic traces convey how clean or noisy data are in a way that is often obscured when the
data is aggregated as they are here and in other such papers. The authors have a chance to make a
major impact, and this is a key piece that would help do so. It would be great to do so for some of the
features so elegantly shown in Fig 4C
Response 21: In this study, we have generated an overwhelming amount of data and have tried to give
the best overview on the data in the main figures. For transparency, we have uploaded all raw data and
processings (MaxQuant and DIA-NN) to ProteomeXchange and everyone interested in using or
reproducing our data is welcome to do so. Accession details can be found in the methods section. We
have also included more supplementary tables in the revised manuscript, reporting raw intensities, and
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p-values and fold changes, when appropriate (see Supplementary Data 1-11). That said, we have
reworked the figures to make them visually more appealing and included more positive controls, such
as the K-GG sites of H2A in Figure 3b or the quantifications of different proteins upon ubiquitin
domain pulldown experiments (Supplementary Figure 6).
To give the best overview of what we think are bona-fide USP7 substrates targeted for proteasomal
degradation, we presented an aggregated heat map with mean Log2 fold changes of downregulated
proteins and their corresponding ubi profiles (averaged signal of significantly-upregulated features.
Figure 4c). The presented comparison of both the proteome and the ubiquitinome are statistically
significant observations. To make the data better accessible to the reader, we included an additional
table (Supplementary Data 8), consisting of a list of proteins and their corresponding ubi sites shown
in the heatmap. In the table, we included raw intensities, fold-changes and p-values of all features. We
hope that this addresses their concern.
Lastly, the one thing that seems missing from this paper is any text describing how the Neural
Networks analysis method operates or how/why it is better. This was a major tenet of impact in the
early text, but was not spoken about in any detail, nor were any demonstrative figures shown.
Response 22: We have thoroughly described and benchmarked the neural network classifier in the
DIA-NN paper https://www.nature.com/articles/s41592-019-0638-x, including library-free mode,
where it’s highly advantageous. We note that since then DIA-NN has improved significantly in many
aspects, including the performance of neural networks, but the general principle of their operation in
DIA-NN remains the same.
In this work, we combine all the advantages of DIA-NN, previously demonstrated for regular
proteomics (without emphasis on modified peptides), with a new PTM-scoring module (described in
detail in the methods section). We show that the resulting workflow substantially outperforms the
previous state-of-the-art software for ubiquitinomics (Spectronaut), and this forms part of the impact
of our work. In addition to the data processing method, our paper also generates an impact by (i)
describing an improved lysis protocol for ubiquitinomics (ii) introducing a new method for
ubiquitinome-signature profiling of drug action at high temporal resolution and (iii) using this method
to profile USP7 action.
Supplementary Figure 7 has the y-axis value truncated in a way that obscures the true result.
Response 23: Thank you for spotting this. We modified the figure (Supplementary Figure 9 of the
revised manuscript).
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On p29, the methods describe two different STAGE tip protocols. When were each used? Are there
any key performance differences between them that might affect data interpretation?
Response 24: For all generated data in this study we used SDB-RPS desalting of peptides, as described
in Methods. The only exception is the urea/SDC comparison of Figure 1. In this case we used
C18-desalting of K-GG peptides for urea lysates, as we were following the protocol published by
Udeshi et al (doi: 10.1038/nprot.2013.120). Please see also the Methods section (Page 40, starting
from line 19).
Reviewer #3 (Remarks to the Author):
The authors describe here a novel workflow for ubiquitomics, the analysis of ubiquitylated proteins in
a biological sample. This workflow is based on a sample preparation protocol using an SDC (sodium
deoxycholate)-based cell lysis, prior to the enrichment of the modification, followed by
data-independent acquisition (DIA) coupled to a neural network-based data processing.
This methodology increases significantly the sensitivity and the throughput of the current GlyGly
peptidome analysis workflow. Finally, the authors applied this workflow to characterise four different
USP7 inhibitors in a colon cancer cell line (HCT116).
General comments:
- The manuscript is well written and clearly presented. However, the use of the English language could
be improved.
Thank you! We tried to improve the language and the manuscript was proofread by a native speaker.
See changes throughout the manuscript.
- The experiments are well designed and the quality of the figures is good.
Thank you, we are glad to hear this!
- This study is of high interest to other researchers in the field. However, a very similar approach,
SDC-based cell lysis followed by DIA analysis) has been published recently in this journal: Hansen, et
al., 2020, https://doi.org/10.1038/s41467-020-20509-1. This takes in part the novelty of this study off.
Response 25: We acknowledge that the Mann lab published a study in which it used SDC lysis and
DIA-MS for ubiquitinomics earlier this year. However, we also note that we posted our manuscript
back-to-back as a preprint on bioRxiv, and this allows us to claim novelty of using DIA for
ubiquitinomics.
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Nonetheless, we cited and discussed the work by Mann and colleagues in the discussion of the original
paper and now included the reference in the first part of the results section (Page 4, line number 9).
Although this study is similar topic-wise, our lysis protocol differs from the protocol applied by
Hansen et al. Moreover, in the revised version of the manuscript, we demonstrate that DIA-NN
significantly outperforms (+ 45%/75% K-GG peptides quantified) the DIA data processing software
used by Hansen et al (i.e. Spectronaut, see Figures 2g, 3e and Supplementary Figure 8 of the revised
manuscript).
Major points:
- Lack of orthogonal validation of the described workflow using more basic biochemistry techniques
to perform ubiquitylation assays. For example, doing GST-UBA pulldowns as in Hansen, et al., 2020
(Fig S3) or performing Ubiquitin immunoprecipitations as in Akimov et al., 2018
(https://doi.org/10.1038/s41594-018-0084-y; Figure 5). This would be particularly interesting for
validating some of the USP7-dependent identified GG peptides.
Response 26: As suggested by the reviewer, we included such a validation experiment in the revised
manuscript. Specifically, we used tandem ubiquitin binding entities (TUBEs) to enrich ubiquitinated
proteins after DMSO/FT671 treatment. To detect all enriched proteins in an unbiased manner and to
precisely quantify them, we use mass spectrometry as readout. Specifically, we digested all proteins
on-bead, followed by MS analysis. This clearly demonstrated that a large fraction of proteins that were
strongly ubiquitinated after 15 minutes of FT671 treatment (see Figure 4 in the manuscript) were also
significantly enriched in the pulldown experiment using ubiquitin domains (Supplementary Figure 6 of
the revised manuscript). These included USP7 and Topors, two of the most strongly regulated proteins
with both assays. Additionally, we confirmed USP7 ubiquitination after FT671 treatment by TUBE
pulldown and Western blotting (Supplementary Figure 6). For changes in the text, please see Page 14,
starting from line 21).
Moreover, for confirming USP7-dependent ubiquitination events, we performed an siRNA-mediated
knockdown of USP7, followed by inhibitor treatment and mass spectrometry-based analysis of the
ubiquitinome. This experiment clearly confirmed that the observed increase in protein ubiquitination is
USP7-dependent. This data is presented in Figure 4 and in Supplementary Figure 5 of the revised
manuscript.
- The acquisition methods (LC-MS/MS measurements) are not comparable for DDA (more
conservative) and DIA (more relaxed) and this could lead to different sensitivities. For instance, I
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consider the average of 4 data points low (8-10 data points would be my recommendation). Table S8
describing the optimisation of the number of DIA segments is missing.
Response 27: First of all, we apologize for  the incorrect assignment of table indices. We intended
Table S4 (now called Supplementary Data 4) and we corrected this in the revised manuscript (Page 42,
lines 7-8).
As for the employed MS methods for DDA and DIA, we used the best performing methods for both
acquisition modes. For  DDA, this is a Top15 method and for DIA, we found that an average of 4-5
data points per peak was the best compromise between identification numbers and precision of
quantification (CVs). As we have shown, our workflow has good precision, significantly better than
DDA, in addition to offering several-fold improvement in identification numbers.
We systematically tested this with 7/6/5/4 data points per peak but did not include the data in the
manuscript in order to keep the manuscript concise. The parameters of the optimized methods as well
as the LC parameters are in Supplementary Data 4.
- ~10% of the GG peptides identified by DDA do not overlap with the GG peptides identified by DIA.
How would you explain this if the DIA method is more sensitive?
Response 28: There are multiple possible explanations for this observation. First of all, the standard
settings in the two softwares are different. For instance, MaxQuant uses 2 missed cleavages per default
while we allowed only one in DIA-NN. As a consequence, some of the peptides will be different when
comparing the two software. Second, DIA will fail to identify peptides which are co-fragmented
together with some co-eluting peptides that produce the same or very close fragment ion masses.
Further, with PTM-enabled searches, any DIA software, be it Spectronaut or DIA-NN, is also forced to
discard all peptide-spectrum matches that do not contain enough evidence for the presence (or
absence) of the modification(s) in the process of PTM scoring. On the other hand, DDA will fail to
identify peptides which are not selected for fragmentation. The ability of DIA to identify substantially
more peptides and with higher data completeness comes, among other things, from the fact that it
misses less peptides than DDA. However, DIA is not guaranteed to identify all the peptides identified
by DDA.
Minor points:
- The authors use USP7 to refer to the human protein. The right nomenclature is USP7 and this should
be amended.
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Apologies for the confusion. We have corrected it throughout the manuscript.
- The authors mention that simultaneously recording the dynamics of both proteome and ubiquitome is
a strategy for capturing USP7 targets or substrates (i.e. in the abstract or on page 11). This is not
correct since these techniques do not provide evidence for direct interaction and we cannot rule out
that the observed effects might be a consequence of secondary ubiquitylation events. The should be
more carefully reformulated across the manuscript.
Response 29: It is true that the observed changes in proteome abundances could be indirect effects and
we believe that many of those are indeed indirect, especially at late time points. However, the evidence
of increased ubiquitination at early time points together with a downregulation of the protein at
intermediate time points (30 min-60 min) represents very strong evidence that these are direct USP7
substrates. We further do not claim that these are bona-fide substrates, as this would need to be
followed up, ideally with an enzymatic assay using purified proteins. We state that ‘...this allows to
pinpoint putative substrates with high confidence’, which we believe is a correct statement.
- deep neural network-based data processing is mentioned several times across the text. A brief
description of such an approach would be useful for gaining access to a broader audience.
Response 30: As we have noted above (Response 22), the advantages of the neural network approach
implemented in DIA-NN are discussed and thoroughly benchmarked in the original DIA-NN paper
(https://www.nature.com/articles/s41592-019-0638-x), while here we have combined this neural
network approach with a PTM scoring module. We demonstrate that this is a very significant
improvement over state-of-the-art for ubiquitinomics (Figures 2, 3 and Supplementary Figure 8). The




Reviewer #1 (Remarks to the Author): 
 
The authors have addressed all my concerns satisfactorily, and I look forward to the publication of 
this manuscript and the related works they mentioned wrt DIA-NN updates. 
 
 
Reviewer #2 (Remarks to the Author): 
 
The authors are commended for assembling an impressive body of work. Their detailed responses to 
the original review have greatly improved what was already a terrific body of work. This paper will 






Reviewer #3 (Remarks to the Author): 
 
The authors satisfactorily addressed my main concerns in the revised version of the manuscript and I 
recommend the publication in its current form. 
Just a couple of very minor comments: 
- Ubiquitinome is correct but ubiquitome or ubiquitylome are also correct (Personally, I prefer 
ubiquitylome). 
- Even if you show changes in ubiquitylation/protein levels at very short times after treatment with 
USP7 inhibitors, that does not mean that these proteins are direct substrates. 
Ubiquitylation/degradation occurs very quickly and intermediate factors might still be involved. 




We again thank all Reviewers for their great work in assessing our manuscript and for their positive 
feedback. We respond to the reviewers comments below. 
Reviewer #1 (Remarks to the Author): 
 
The authors have addressed all my concerns satisfactorily, and I look forward to the publication of this 
manuscript and the related works they mentioned wrt DIA-NN updates. 
Thank you very much! 
 
 
Reviewer #2 (Remarks to the Author): 
 
The authors are commended for assembling an impressive body of work. Their detailed responses to 
the original review have greatly improved what was already a terrific body of work. This paper will be 
impactful for both the MS proteomics and the ubiquitin research communities. 
 




Reviewer #3 (Remarks to the Author): 
 
The authors satisfactorily addressed my main concerns in the revised version of the manuscript and I 
recommend the publication in its current form. 
Thank you! 
 
Just a couple of very minor comments: 
- Ubiquitinome is correct but ubiquitome or ubiquitylome are also correct (Personally, I prefer 
ubiquitylome). 
We fully agree that both terms are used. We added one sentence in the introduction making it clear 
that the two terms are interchangeable (Page 4, third paragraph). 
 
- Even if you show changes in ubiquitylation/protein levels at very short times after treatment with 
USP7 inhibitors, that does not mean that these proteins are direct substrates. 
Ubiquitylation/degradation occurs very quickly and intermediate factors might still be involved. 
Additional interactomics, proximity labelling, and biochemical analyses would be required to be fully 
confident. 
 
We agree that no standalone assay can interrogate an enzyme-substrate relationship satisfactorily and 
that orthogonal assays are required for this. We added the following sentence to the discussion (Page 
13, first paragraph):  
By doing so, early-induced ubiquitination events on a target protein can be connected to its 
degradation at later time points, allowing the pinpointing of putative substrates with high confidence. 
Nevertheless, to confirm direct DUB targets, orthogonal assays such in vitro deubiquitination assays 
or proximity-labeling experiments are required. 
